Treatment of ECL cell carcinoids with octreotide LAR

References

• Solcia E, Capella C, Sessa F, Rindi G, Cornaggia M, Riva C, et al. Gastric carcinoids and related endocrine growths. Digestion 1986;35 Suppl 1:3–22.
   PubMed Web of Science ®Google Scholar
• Havu N, Maaroos HI, Sipponen P. Argyrophil cell hyperplasia associated with chronic corpus gastritis in gastric ulcer disease. Scand J Gastroenterol 1991;Suppl 186:90–4.
   Google Scholar
• Creutzfeldt W, Lamberts R. Inter-relationship between serum gastrin levels, gastric mucosal histology and gastric endocrine cell growth. Digestion 1992;51 Suppl 1:76–81.
   PubMed Web of Science ®Google Scholar
• Kokkola A, Sjoblom SM, Haapiainen R, Sipponen P, Puolakkainen P, Jarvinen H. The risk of gastric carcinoma and carcinoid tumours in patients with pernicious anaemia. A prospective follow-up study. Scand J Gastroenterol 1998;33:88–92.
   PubMed Web of Science ®Google Scholar
• Borch K, Renvall H, Liedberg G. Gastric endocrine cell hyperplasia and carcinoid tumors in pernicious anemia. Gastroenterology 1985;88:638–48.
   Google Scholar
• Bordi C, Yu JY, Baggi MT, Davoli C, Pilato FP, Baruzzi G, et al. Gastric carcinoids and their precursor lesions. A histologic and immunohistochemical study of 23 cases. Cancer 1991;67:663–72.
   Google Scholar
• Rindi G, Luinetti O, Cornaggia M, Capella C, Solcia E. Three subtypes of gastric argyrophil carcinoid and the gastric neuroendocrine carcinoma: a clinicopathologic study. Gastroenterology 1993;104:994–1006.
   Google Scholar
• Godwin JD. Carcinoid tumors. An analysis of 2,837 cases. Cancer 1975;36: 560–9.
   Google Scholar
• Modlin IM, Sandor A. An analysis of 8305 cases of carcinoid tumors. Cancer 1997;79:813–29.
   PubMed Web of Science ®Google Scholar
• Rindi G, Bordi C, Rappel S, La Rosa S, Stolte M, Solcia E. Gastric carcinoids and neuroendocrine carcinomas: pathogenesis, pathology, and behavior. World J Surg 1996;20:168–72.
   Google Scholar
• Ryberg B, Tielemans Y, Axelson J, Carlsson E, Hakanson R, Mattson H, et al. Gastrin stimulates the self-replication rate of enterochromaffinlike cells in the rat stomach. Effects of omeprazole, ranitidine, and gastrin-17 in intact and antrectomized rats. Gastroenterology 1990;99: 935–42.
   Google Scholar
• Håkanson R, Tielemans Y, Chen D, Andersson K, Mattsson H, Sundler F. Time-dependent changes in enterochromaffin-like cell kinetics in stomach of hypergastrinemic rats. Gastroenterology 1993;105:15–21.
   Google Scholar
• Eckhauser FE, Lloyd RV, Thompson NW, Raper SE, Vinik AI. Antrectomy for multicentric, argyrophil gastric carcinoids: a preliminary report. Surgery 1988;104:1046–53.
   Google Scholar
• Kern SE, Yardley JH, Lazenby AJ, Boitnott JK, Yang VW, Bayless TM, et al. Reversal by antrectomy of endocrine cell hyperplasia in the gastric body in pernicious anemia: a morphometric study. Mod Pathol 1990;3:561–6.
   PubMed Web of Science ®Google Scholar
• Guillem P, Vlaeminck-Guillem V, Leteurtre E, Kornhauser R, Cortot A, Wemeau JL, et al. Fundic endocrine tumors and atrophic gastritis: the value of antrectomy. Gastroenterol Clin Biol 2002;26:782–5.
   PubMedGoogle Scholar
• Modlin IM, Gilligan CJ, Lawton GP, Tang LH, West AB, Darr U. Gastric carcinoids. The Yale experience. Arch Surg 1995; 130: 250–5.
   PubMedGoogle Scholar
• Qvigstad G, Falkmer S, Westre B, Waldum HL. Clinical and histopathological tumour progression in ECL cell carcinoids (‘ECLomas’). APMIS 1999;107:1085–92.
   PubMed Web of Science ®Google Scholar
• Prinz C, Sachs G, Walsh JH, Coy DH, Wu SV. The somatostatin receptor subtype on rat enterochromaffin-like cells. Gastroenterology 1994;107:1067–74.
   Google Scholar
• D’Adda T, Annibale B, Delle FG, Bordi C. Oxyntic endocrine cells of hypergastrinaemic patients. Differential response to antrectomy or octreotide. Gut 1996;38:668–74.
   Google Scholar
• Higham AD, Dimaline R, Varro A, Attwood S, Armstrong G, Dockray GJ, et al. Octreotide suppression test predicts beneficial outcome from antrectomy in a patient with gastric carcinoid tumor. Gastroenterology 1998;114:817–22.
   PubMed Web of Science ®Google Scholar
• Ferraro G, Annibale B, Marignani M, Azzoni C, D’Adda T, D’Ambra G, et al. Effectiveness of octreotide in controlling fasting hypergastrinemia and related enterochromaffin-like cell growth. J Clin Endocrinol Metab 1996;81:677–83.
   Google Scholar
• Bakke I, Sandvik AK, Waldum HL. Octreotide inhibits the enterochromaffin-like cell but not peroxisome proliferator-induced hypergastrinemia. J Mol Endocrinol 2000;25:109–19.
   Google Scholar
• Burgess JR, Greenaway TM, Parameswaran V, Shepherd JJ. Octreotide improves biochemical, radiologic, and symptomatic indices of gastroenteropancreatic neoplasia in patients with multiple endocrine neoplasia type 1 (MEN-1). Implications for an integrated model of MEN-1 tumorigenesis. Cancer 1999;86: 2154–9.
   Google Scholar
• Tomassetti P, Migliori M, Caletti GC, Fusaroli P, Corinaldesi R, Gullo L. Treatment of type II gastric carcinoid tumors with somatostatin analogues. N Engl J Med 2000;343:551–4.
   PubMed Web of Science ®Google Scholar
• Prommegger R, Bale R, Ensinger C, Sauper T, Profanter C, Knoflach M, et al. Gastric carcinoid type I tumour: new diagnostic and therapeutic method. Eur J Gastroenterol Hepatol 2003; 15:705–7.
   PubMed Web of Science ®Google Scholar
• Garland J, Buscombe JR, Bouvier C, Bouloux P, Chapman MH, Chow AC, et al. Sandostatin LAR (long-acting octreotide acetate) for malignant carcinoid syndrome: a 3-year experience. Aliment Pharmacol Ther 2003;17:437–44.
   PubMed Web of Science ®Google Scholar
• Ayuk J, Stewart SE, Stewart PM, Sheppard MC. Long-term safety and efficacy of depot long-acting somatostatin analogs for the treatment of acromegaly. J Clin Endocrinol Metab 2002;87: 4142–6.
   PubMed Web of Science ®Google Scholar
• Qvigstad G, Sandvik AK, Brenna E, Aase S, Waldum HL. Detection of chromogranin A in human gastric adenocarcinomas using a sensitive immunohistochemical technique. Histochem J 2000;32:551–6.
   Google Scholar
• Sevier AC, Munger BL. Technical note: a silver method for paraffin sections of neural tissue. J Neuropathol Exp Neurol 1965;24:130–5.
   PubMed Web of Science ®Google Scholar
• Kleveland PM, Haugen SE, Waldum HL. The preparation of bioactive 125I-gastrin, using Iodo-gen as oxidizing agent, and the use of this tracer in receptor studies. Scand J Gastroenterol 1985;20: 569–76.
   Google Scholar
• Syversen U, Jacobsen MB, O’Connor DT, Ronning K, Waldum HL. Immunoassays for measurement of chromogranin A and pancreastatin-like immunoreactivity in humans: correspondence in patients with neuroendocrine neoplasia. Neuropeptides 1994; 26:201–6.
   Google Scholar
• Modlin IM, Kumar R, Nangia A, Soroka CJ, Pasikhov D, Goldenring JR. Gastrin-dependent inhibitory effects of octreotide on the genesis of gastric ECLomas. Surgery 1992;112:1048–56.
   PubMed Web of Science ®Google Scholar
• Borch K, Stridsberg M, Burman P, Rehfeld JF. Basal chromogranin A and gastrin concentrations in circulation correlate to endocrine cell proliferation in type-A gastritis. Scand J Gastroenterol 1997;32:198–202.
   PubMed Web of Science ®Google Scholar
• Waldum HL, Syversen U. Chromogranin A (CGA) and the enterochromaffin-like (ECL) cell. Adv Exp Med Biol 2000;482: 361–7.
   PubMed Web of Science ®Google Scholar
• Takiyyuddin MA, Baron AD, Cervenka JH, Barbosa JA, Neumann HP, Parmer RJ, et al. Suppression of chromogranin-A release from neuroendocrine sources in man: pharmacological studies. J Clin Endocrinol Metab 1991;72:616–22.
   PubMed Web of Science ®Google Scholar
• Rindi G, Azzoni C, La Rosa S, Klersy C, Paolotti D, Rappel S, et al. ECL cell tumor and poorly differentiated endocrine carcinoma of the stomach: prognostic evaluation by pathological analysis. Gastroenterology 1999;116:532–42.
   PubMed Web of Science ®Google Scholar
• Brenna E, Waldum HL. Trophic effect of gastrin on the enterochromaffin like cells of the stomach: establishment of a dose response relationship. Gut 1992;33:1303–6.
   PubMed Web of Science ®Google Scholar